title: Clinical development plan: N-(4-hydroxyphenyl)retinamide.
authors.affiliation: Chemoprevention Branch, National Cancer Institute (NCI), Bethesda, MD 20892, USA.
authors.forename: G J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: J A
authors.initials: JA
authors.lastname: Crowell
authors.forename: C W
authors.initials: CW
authors.lastname: Boone
authors.forename: V E
authors.initials: VE
authors.lastname: Steele
authors.forename: R A
authors.initials: RA
authors.lastname: Lubet
authors.forename: P
authors.initials: P
authors.lastname: Greenwald
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
authors.forename: J M
authors.initials: JM
authors.lastname: Covey
authors.forename: L A
authors.initials: LA
authors.lastname: Doody
authors.forename: G G
authors.initials: GG
authors.lastname: Knapp
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards; D006224:Cricetinae; D004285:Dogs; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical / Q000592:standards; D017313:Fenretinide / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D051381:Rats; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control
chemical_list: D017313:Fenretinide